Mikhail Blagosklonny is a professor, oncologist and medical researcher. He teaches Oncology at the Roswell Park Cancer Institute located in New York. Dr. Mikhail studies and focuses on research that aims to create anti-aging treatments. He attended the First Pavlov State University, where he earned his Master’s degree. Mikhail Blagosklonny also holds a Doctorate in Experimental Medicine. His research revolves around cancer and tumors.
Mikhail began his career as an associate professor at the New York Medical College in 2002. After some time, he left the institution to work as a senior scientist at the Ordway Research Institute. In 2019, he decided to join Roswell Park Cancer Center. Dr. Blagosklonny conducts research in the areas of cellular biology at Roswell. He mainly concentrates on cellular senescence, anti-cancer therapeutics, and signal transduction.
Mikhail Blagosklonny has a lot of knowledge and experience in oncology. Over the years, he has helped develop solutions for cancer patients and his fellow oncologists. Also, he has developed an interest in creating effective cancer therapies. Mikhail Blagosklonny has a passion for developing drug therapies that can kill cancer cells as well as protect the healthy cells. He is actively involved in studies that focus on developing anti-aging medicine.
Read more: http://www.aging-us.com/article/100591/text
Recently, Dr. Mikhail established that treatments used to suppress cancer could help delay the aging process. His research enabled him to come up with a postulate on how to use TOR signaling in aging and cancer. He proposed the use of rapamycin as an anti-aging solution. This drug is used to suppress tumors, so it can be used to extend the life expectancy of cancer patients -according to Dr. Mikhail theory. Blagosklonny is among the medical scholars who’ve researched on the drug thoroughly. Therefore, he knows it can prolong the life of healthy individuals.
Mikhail Blagosklonny has published reviews, articles, chapters in medical books and 300 research papers. He founded Oncotartget in 2010 to help researchers share information about cancer treatment. Oncortaget is an oncology journal published every week. Dr. Mikhail and Andrei Gudkov are the chief editors of the publication. The type of research material published on Oncotarget includes endocrinology, cell biology, biotechnology, aging, and oncology. Thanks to Mikhail Blagosklonny leadership, Oncotarget is now one of the most popular oncology journals in the world. It has an average impact factor of 5.0. This means that a lot of readers value the information offered on the journal.
Blagosklonny is a senior editor for Cell Cycle, a leading medical journal. Additionally, he’s an associate editor of the International Journal of Cancer, Autophagy, PLOS ONE and Cell Death & Differentiation Journal. Mikhail Blagosklonny research papers have been cited over 30,000 times in various publications. These citations have made Dr. Mikhail one of the best medical researchers globally. His h-index stands at 83. Check Mikhail’s profile in LinkedIn